Role of cAMP‐dependent protein kinase (PKA) in opioid agonist‐induced μ‐opioid receptor downregulation and tolerance in mice

Studies suggest that acute and chronic opioids can regulate the cAMP‐dependent protein kinase (PKA) signaling pathway and that changes in this pathway may be involved in opioid tolerance. In the present study, we examined the role of cAMP‐PKA on μ‐opioid receptor downregulation and tolerance in mice. Mice were injected intracerebroventricular (i.c.v.) and intrathecal (i.t.) once a day with an antisense oligodeoxynucleotide directed at the mRNA for the α catalytic subunit of mouse PKA. Controls were treated with saline or a mismatch oligodeoxynucleotide. On day 2 of treatment, mice were implanted s.c. with a 25‐mg morphine pellet and an osmotic minipump infusing morphine (40 mg/kg/day) for 3 days. Other mice were implanted with an osmotic minipump infusing etorphine (125, 250 μg/kg/day) for 2 days. Control mice were implanted s.c. with inert placebo pellets. At the end of treatment, pumps and pellets were removed and mice tested for morphine or etorphine analgesia. Other mice were sacrificed and μ‐opioid receptor binding assays conducted in whole brain. Both infusion doses of etorphine produced significant tolerance (ED50 shift = 3.6 and 6.3‐fold). The higher etorphine infusion produced downregulation of μ‐receptor density (≈30%) while the lower infusion dose of etorphine did not. Morphine treatment also produced significant tolerance in mice (ED50 shift = 4.5‐fold), but no receptor downregulation. Antisense to PKA partially blocked tolerance induced by the higher dose of etorphine, but had no effect on receptor downregulation. On the other hand, antisense to PKA completely blocked tolerance induced by morphine and the lower infusion dose of etorphine. The mismatch oligodeoxynucleotide had no effect on any measure. These results suggest that PKA has a limited role in opioid agonist‐induced receptor downregulation. However, the partial block of tolerance for the high infusion dose of etorphine and the complete block of tolerance for morphine and the low infusion dose of etorphine suggests that PKA may play a critical role in tolerance that is “receptor‐regulation‐independent.” Synapse 38:322–327, 2000. © 2000 Wiley‐Liss, Inc.

[1]  A. Duttaroy,et al.  In vivo regulation of μ‐opioid receptor density and gene expression in CXBK and outbred Swiss Webster mice , 2000 .

[2]  E. J. Simon,et al.  Role of Protein Kinase C (PKC) in Agonist‐Induced α‐Opioid Receptor Down‐Regulation , 1999 .

[3]  E. J. Simon,et al.  Role of Protein Kinase C (PKC) in Agonist‐Induced μ‐Opioid Receptor Down‐Regulation , 1999 .

[4]  D. Colquhoun.  Pharmacologic Analysis of Drug–Receptor Interaction (3rd edn) , 1998 .

[5]  J. Whistler,et al.  Morphine-activated opioid receptors elude desensitization by β-arrestin , 1998 .

[6]  H. Loh,et al.  Distinct Differences Between Morphine‐ and [d‐Ala2,N‐MePhe4,Gly‐ol5]‐Enkephalin‐ μ‐Opioid Receptor Complexes Demonstrated by Cyclic AMP‐Dependent Protein Kinase Phosphorylation , 1998, Journal of neurochemistry.

[7]  M. Caron,et al.  Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[8]  H. Loh,et al.  Immunohistochemical evidence of down-regulation of mu-opioid receptor after chronic PL-017 in rats. , 1998, European journal of pharmacology.

[9]  D. Lissin,et al.  mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain. , 1998, Molecular pharmacology.

[10]  W. Sadee,et al.  Specific G protein activation and mu-opioid receptor internalization caused by morphine, DAMGO and endomorphin I. , 1998, European journal of pharmacology.

[11]  A. Duttaroy,et al.  In vivo homologous regulation of mu-opioid receptor gene expression in the mouse. , 1997, European journal of pharmacology.

[12]  G. Uhl,et al.  μ Opioid Receptor Phosphorylation, Desensitization, and Ligand Efficacy* , 1997, The Journal of Biological Chemistry.

[13]  G. Aghajanian,et al.  Molecular and cellular basis of addiction. , 1997, Science.

[14]  C. Inturrisi,et al.  Activation of protein kinase A prevents the ethanol-induced up-regulation of δ-opioid receptor mRNA in NG108-15 cells , 1997 .

[15]  G. Gessa,et al.  Chronic morphine and naltrexone fail to modify mu-opioid receptor mRNA levels in the rat brain. , 1997, Brain research. Molecular brain research.

[16]  B. Cox,et al.  Regulation of δ‐Opioid Receptor mRNA Levels by Receptor‐Mediated and Direct Activation of the Adenylyl Cyclase‐Protein Kinase A Pathway , 1997 .

[17]  L. Devi,et al.  Sequestration of the delta opioid receptor. Role of the C terminus in agonist-mediated internalization. , 1996, The Journal of biological chemistry.

[18]  M. von Zastrow,et al.  Agonist-selective endocytosis of mu opioid receptor by neurons in vivo. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Christopher J. Evans,et al.  Morphine Activates Opioid Receptors without Causing Their Rapid Internalization* , 1996, The Journal of Biological Chemistry.

[20]  B. Cox,et al.  Mu and delta opioid receptor gene expression after chronic treatment with opioid agonist. , 1996, Neuroreport.

[21]  F. F. Weight,et al.  Differential Opiate Receptor Phosphorylation and Desensitization Induced by Agonists and Phorbol Esters (*) , 1996, The Journal of Biological Chemistry.

[22]  B. Roth,et al.  5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. , 1995, The Journal of pharmacology and experimental therapeutics.

[23]  W. Klee,et al.  Agonist regulation of the expression of the delta opioid receptor in NG108‐15 cells , 1995, FEBS letters.

[24]  M. Narita,et al.  Inhibition of protein kinase C, but not of protein kinase A, blocks the development of acute antinociceptive tolerance to an intrathecally administered mu-opioid receptor agonist in the mouse. , 1995, European journal of pharmacology.

[25]  A. Duttaroy,et al.  The Effect of Intrinsic Efficacy on Opioid Tolerance , 1995, Anesthesiology.

[26]  A. Duttaroy,et al.  Opioid receptor regulation in mice. , 1993, The Journal of pharmacology and experimental therapeutics.

[27]  B. Carter,et al.  Receptor mechanisms of opioid tolerance in SH-SY5Y human neural cells. , 1993, Molecular pharmacology.

[28]  B. Cox,et al.  Selective changes in mu opioid receptor properties induced by chronic morphine exposure. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Duman,et al.  Acute and chronic opiate-regulation of adenylate cyclase in brain: specific effects in locus coeruleus. , 1988, The Journal of pharmacology and experimental therapeutics.

[30]  J. Tallman,et al.  Chronic morphine treatment increases cyclic AMP-dependent protein kinase activity in the rat locus coeruleus. , 1988, Molecular pharmacology.

[31]  H. Loh,et al.  Opiate receptor down-regulation and desensitization in neuroblastoma X glioma NG108-15 hybrid cells are two separate cellular adaptation processes. , 1983, Molecular pharmacology.

[32]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[33]  M. von Zastrow,et al.  Morphine-activated opioid receptors elude desensitization by beta-arrestin. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Uhl,et al.  Mu opioid receptor phosphorylation, desensitization, and ligand efficacy. , 1997, The Journal of biological chemistry.

[35]  B. Cox,et al.  Regulation of delta-opioid receptor mRNA levels by receptor-mediated and direct activation of the adenylyl cyclase-protein kinase A pathway. , 1997, Journal of neurochemistry.

[36]  C. Inturrisi,et al.  Activation of protein kinase A prevents the ethanol-induced up-regulation of delta-opioid receptor mRNA in NG108-15 cells. , 1997, Brain research. Molecular brain research.

[37]  Terrence P. Kenakin,et al.  A Pharmacologic Analysis of Drug-Receptor Interaction , 1987 .